The Law Society of England and Wales has sounded the alarm that scrapping the UK’s opt‑out collective actions regime would invite a surge in unchecked anti‑competitive conduct by multinational firms.

An article in the Law Society Gazette explains that the UK government is reviewing its collective redress regime—introduced in 2015 under the Competition Appeal Tribunal (CAT) framework—to determine whether it remains appropriate for businesses and consumers alike. Above all, the bar warns that eliminating or substantially reducing the ability of groups of consumers to act together would remove a key check on large firms’ power.

According to the bar’s statement, collective actions provide a vital counterbalance: they allow individuals with smaller claims (often against powerful enterprise defendants) to combine resources, reduce costs, and obtain meaningful relief. Without that mechanism, the risk is that dominant players may routinely engage in cartel‑type behaviour, abuse market position or otherwise infringe competition law with little fear of private litigation.

The review highlights that the regime has evolved faster than anticipated: the original design assumed most cases would follow a finding by the competition authority, but in practice around 90% are now “stand‑alone” claims brought without a prior regulatory decision.

For the legal funding and litigation finance sector, this development is especially consequential. Were collective actions to be scaled back or abolished, the landscape for financing competition‑law claims would shift markedly: fewer aggregated opportunities, higher individual‑case risk, and potentially lower investor appetite. It raises key questions about the future viability of funding models that rely on class‑style litigation in the UK market.

A healthcare‑turned‑litigation investor has taken legal action against Lake Law Firm and its partner Ed Lake, alleging a sweeping investment failure in the mass‑tort financing space. According to the complaint filed in New York State Supreme Court on October 22, the investor pumped around $5.3 million into programs tied to hernia‑mesh, Bayer AG’s RoundUp, 3M Co., and Johnson & Johnson talcum‑powder claims — only to find that fewer than the promised number of cases ever materialized.

An article in Bloomberg notes that per the suit, the law firm had committed to signing up 113 hernia‑mesh cases, 100 3M cases, and 50 RoundUp matters, but delivered only 15, 40, and 8 respectively. Separately, Lake Law pledged submission of 8,000 applications under the federal Covid‑era Employee Retention Credit program, yet managed only 2,655. The complaint characterizes the structure as “more akin to a Ponzi scheme than a legitimate litigation‐finance program.”

The investor also alleges that the law firm defaulted on a “case‑replacement agreement,” and is now demanding $6.2 million in damages, plus rights to any mass‑tort profits and tax‑credit claims that “rightfully belong” to him. According to the filing, his wife had separately invested $2.5 million and likewise filed suit last week claiming non‑repayment.